Forest's Bystolic draws FDA warning letter
This article was originally published in Scrip
Executive Summary
The US FDAhas warned Forest Laboratoriesthat an eight-page launch advert for its antihypertensive Bystolic (nebivolol) makes unsubstantiated superiority, mechanism of action, and efficacy claims. It also misleadingly implies that the tolerability of the drug is better than that of other beta-adrenergic receptor blocking agents.